What is NanoDx?
NanoDx operates at the intersection of nanotechnology and clinical diagnostics, focusing on the development of advanced biosensor platforms. By miniaturizing complex diagnostic processes, the company aims to provide rapid, accurate, and accessible health data. This technological approach is designed to address critical gaps in current medical testing, offering a scalable solution that can be integrated into various healthcare environments. As the firm matures, its market position is defined by its ability to bridge the gap between high-level laboratory precision and the immediate needs of clinical settings, thereby enhancing the efficiency of healthcare delivery systems worldwide.
How much funding has NanoDx raised?
NanoDx has raised a total of $30.5M across 7 funding rounds:
Series A
$4M
Private Equity
$1.6M
Series B
$4M
Private Equity
$2M
Private Equity
$557K
Debt
$350K
Series C
$18M
Series A (2013): $4M, investors not publicly disclosed
Private Equity (2014): $1.6M, investors not publicly disclosed
Series B (2016): $4M supported by Provident Healthcare Capital
Private Equity (2017): $2M featuring Provident Healthcare Capital and MedScience Ventures, LLC
Private Equity (2017): $557K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Series C (2020): $18M led by Shepherd Kaplan Krochuk, LLC
Key Investors in NanoDx
Provident Healthcare Capital
Provident Healthcare Partners is a specialized healthcare investment banking firm providing strategic advisory, mergers and acquisitions, and equity financing services to private healthcare entities.
MedScience Ventures, LLC
MedScience Ventures, LLC focuses on fostering innovation within the life sciences sector through strategic investments and collaborative partnerships.
Shepherd Kaplan Krochuk, LLC
Shepherd Kaplan Krochuk, LLC is an investment management firm that provides strategic capital to support the growth and scaling of innovative enterprises.
What's next for NanoDx?
With the successful closure of its latest financing round, NanoDx is well-positioned to scale its operational infrastructure and expand its research and development initiatives. The strategic focus will likely shift toward regulatory milestones and the commercialization of its biosensor technology. By utilizing this capital to strengthen its market presence, the company is poised to address the increasing demand for decentralized diagnostic tools. Future growth will depend on the firm's ability to navigate complex healthcare regulations while maintaining the technical integrity of its platform, ensuring that its diagnostic solutions remain at the forefront of medical innovation.
See full NanoDx company page
